University of California San Francisco

Publications

  1. Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.
    Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A
    Blood Adv. 2026 Feb 10; 10(3):837-849.; 
    PubMed
  2. Lineage-tracing hematopoietic stem cell origins in vivo to efficiently make human HLF+ HOXA+ hematopoietic progenitors from pluripotent stem cells.
    Fowler JL, Zheng SL, Nguyen A, Chen A, Xiong X, Chai T, Chen JY, Karigane D, Banuelos AM, Niizuma K, Kayamori K, Nishimura T, Cromer MK, Gonzalez-Perez D, Mason C, Liu DD, Yilmaz L, Miquerol L, Porteus MH, Luca VC, Majeti R, Nakauchi H, Red-Horse K, Weissman IL, Ang LT, Loh KM
    PubMed
  3. Protocol for efficient CRISPR/AAV-mediated genome editing and erythroid differentiation of human hematopoietic stem and progenitor cells.
    Sharma D, Sinha R, Lesch BJ, Cromer MK
    STAR Protoc. 2025 Sep 19; 6(3):104018.; 
    PubMed
  4. Dual α-globin-truncated erythropoietin receptor knockin restores hemoglobin production in α-thalassemia-derived erythroid cells.
    Chu SN, Soupene E, Sharma D, Sinha R, McCreary T, Hernandez B, Shen H, Wienert B, Bowman C, Yin H, Lesch BJ, Jia K, Romero KA, Kostamo Z, Zhang Y, Tran T, Cordero M, Homma S, Hampton JP, Gardner JM, Conklin BR, MacKenzie TC, Sheehan VA, Porteus MH, Cromer MK
    Cell Rep. 2025 01 28; 44(1):115141.; 
    PubMed
  5. Mobilization meets antibody conditioning: A path toward safer engraftment.
    Cromer MK
    Mol Ther. 2025 Oct 01; 33(10):4673-4675.; 
    PubMed
  6. Highly efficient in vivo hematopoietic stem cell transduction using an optimized self-complementary adeno-associated virus.
    Charlesworth CT, Homma S, Amaya AK, Dib C, Vaidyanathan S, Tan TK, Miyauchi M, Nakauchi Y, Suchy FP, Wang S, Igarashi KJ, Cromer MK, Dudek AM, Amorin A, Czechowicz A, Wilkinson AC, Nakauchi H
    PubMed
  7. In vivo site-specific engineering to reprogram T cells.
    Nyberg WA, Bernard PL, Ngo W, Wang CH, Ark J, Rothrock A, Borgo GM, Kimmerly GR, Jung JH, Allain V, Hamilton JR, Baldwin A, Stickels R, Wyman S, Khan SH, Lang S, Marsh D, Almudhfar N, Novick C, Mortazavi Y, Zhang S, AbdElwakil MM, Sandoval LR, Hwang S, Chu SN, Jung H, Liu C, Sharma D, McCreary T, Li Z, Satpathy AT, Carnevale J, Rutishauser RL, Cromer MK, Roybal KT, Dodgson SE, Doudna JA, Asokan A, Eyquem J
    Nature. 2026 04; 652(8110):712-721.; 
    PubMed
  8. Enhancement of erythropoietic output by Cas9-mediated insertion of a natural variant in haematopoietic stem and progenitor cells.
    Luna SE, Camarena J, Hampton JP, Majeti KR, Charlesworth CT, Soupene E, Selvaraj S, Jia K, Sheehan VA, Cromer MK, Porteus MH
    Nat Biomed Eng. 2024 12; 8(12):1540-1552.; 
    PubMed
  9. Lentiviral vectors for hematopoietic stem cell gene therapy restore α-globin expression in α-thalassemia red blood cells.
    Segura EER, Hart K, Campo Fernandez B, Brown D, Tam K, Gutierrez Garcia A, Seigneurbieux E, Li K, Mulumba C, Blakely E, Masiuk K, Sinha R, Sharma D, Everett J, Hogenauer M, Cromer MK, Bushman F, MacKenzie TC, Kohn DB
    Cell Rep Med. 2025 Oct 21; 6(10):102362.; 
    PubMed
  10. Engineering synthetic signaling receptors to enable erythropoietin-free erythropoiesis.
    Shah AP, Majeti KR, Ekman FK, Selvaraj S, Sharma D, Sinha R, Soupene E, Chati P, Luna SE, Charlesworth CT, McCreary T, Lesch BJ, Tran T, Chu SN, Porteus MH, Kyle Cromer M
    Nat Commun. 2025 Jan 29; 16(1):1140.; 
    PubMed